Vaccinex, Inc.

OTCPK:VCNX Stock Report

Market Cap: US$1.8m

Vaccinex Management

Management criteria checks 3/4

Vaccinex's CEO is Maurice Zauderer, appointed in Apr 2001, has a tenure of 24.08 years. total yearly compensation is $447.99K, comprised of 97.6% salary and 2.4% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $2.40K. The average tenure of the management team and the board of directors is 10.2 years and 22.2 years respectively.

Key information

Maurice Zauderer

Chief executive officer

US$448.0k

Total compensation

CEO salary percentage97.6%
CEO tenure24.1yrs
CEO ownership0.1%
Management average tenure10.2yrs
Board average tenure22.2yrs

Recent management updates

Recent updates

Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use Debt

Aug 17
Rock star Growth Puts Vaccinex (NASDAQ:VCNX) In A Position To Use Debt

CEO Compensation Analysis

How has Maurice Zauderer's remuneration changed compared to Vaccinex's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024US$448kUS$437k

-US$19m

Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$19m

Dec 31 2023US$430kUS$412k

-US$20m

Sep 30 2023n/an/a

-US$22m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$425kUS$401k

-US$20m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$20m

Mar 31 2022n/an/a

-US$20m

Dec 31 2021US$402kUS$375k

-US$22m

Sep 30 2021n/an/a

-US$24m

Jun 30 2021n/an/a

-US$28m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020US$444kUS$357k

-US$29m

Sep 30 2020n/an/a

-US$29m

Jun 30 2020n/an/a

-US$28m

Mar 31 2020n/an/a

-US$30m

Dec 31 2019US$399kUS$347k

-US$32m

Sep 30 2019n/an/a

-US$34m

Jun 30 2019n/an/a

-US$33m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$337kUS$337k

-US$30m

Compensation vs Market: Maurice's total compensation ($USD447.99K) is below average for companies of similar size in the US market ($USD662.66K).

Compensation vs Earnings: Maurice's compensation has increased whilst the company is unprofitable.

CEO

Maurice Zauderer (78 yo)

24.1yrs

Tenure

US$447,988

Compensation

Dr. Maurice Zauderer, Ph.D. Co-Founded Vaccinex, Inc. in April 2001 and also serves as its President and Chief Executive Officer since April 2001. Dr. Zauderer serves as Director of Vaccinex Inc. since Apr...

Leadership Team

NamePositionTenureCompensationOwnership
Maurice Zauderer
Co-Founder24.1yrsUS$447.99k0.13%
$ 2.4k
Elizabeth Evans
COO and Senior VP of Discovery & Translational Medicine4yrsUS$317.05k0.0017%
$ 30.7
Ernest Smith
Senior VP of Research & Chief Scientific Officer16.4yrsUS$347.52k0.0015%
$ 26.0
Jill Sanchez
Chief Financial Officer1.2yrsno datano data

10.2yrs

Average Tenure

52yo

Average Age

Experienced Management: VCNX's management team is seasoned and experienced (10.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Maurice Zauderer
Co-Founder24.1yrsUS$447.99k0.13%
$ 2.4k
Gerald Van Strydonck
Independent Director22.2yrsUS$90.00k0.020%
$ 361.7
Anthony Tolcher
Scientific and Clinical Advisorno datano datano data
Max Vasquez
Member of Scientific & Clinical Advisory Boardno datano datano data
Mark Tullman
Scientific and Clinical Advisorno datano datano data
Khurram Bashir
Scientific and Clinical Advisorno datano datano data
Albert Friedberg
Chairman of the Board24.1yrsno data0.078%
$ 1.4k
Laura Balcer
Scientific & Clinical Advisorno datano datano data
Peter Calabresi
Scientific & Clinical Advisorno datano datano data
Jeffrey Cohen
Scientific & Clinical Advisorno datano datano data
Barbara Yanni
Independent Director10.3yrsUS$85.00k0%
$ 0
Jacob Frieberg
Independent Lead Director10.3yrsUS$75.00k0.063%
$ 1.1k

22.2yrs

Average Tenure

77yo

Average Age

Experienced Board: VCNX's board of directors are seasoned and experienced ( 22.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/04 16:47
End of Day Share Price 2025/05/02 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vaccinex, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Thomas ShraderBTIG
Matthew KaplanLadenburg Thalmann & Company
Leland GershellOppenheimer & Co. Inc.